Neurotransmitters in Alzheimer's disease;Neurotransmisores en la enfermedad de Alzheimer

Revista de Neurologia

Volumn 42, Issue 6, 2006, Pages 350-353

  Manzano Palomo, S ^a   De La Morena Vicente, M A ^a   Barquero, M S ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Acetylcholine; Alzheimer's disease; Muscarinic receptors; Neurotransmitters; Nicotinic receptors

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; NEUROPEPTIDE; NEUROTRANSMITTER; ACETYLCHOLINE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CHOLINESTERASE INHIBITOR; DOPAMINE; SEROTONIN;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; ENZYME INHIBITION; HUMAN; MONOAMINERGIC SYSTEM; NEUROPROTECTION; NEUROTRANSMISSION; NORADRENERGIC SYSTEM; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; REVIEW; SEROTONINERGIC SYSTEM; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHOLINESTERASE INHIBITORS; DOPAMINE; HUMANS; NEUROPEPTIDES; NEUROTRANSMITTER AGENTS; SEROTONIN; SYNAPTIC TRANSMISSION;

EID: 33749183746     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4206.2005219     Document Type: Review

References (26)

1. Martínez-Lage JM. Patología colinérgica y no colinérgica en la enfermedad de Alzheimer. In Alberca R, López-Pousa S, eds. Enfermedad de Alzheimer y otras demencias. Madrid: Médica Panamericana; 2002. p. 199-210.
2. Davies P, Maloney AJF. Selective loss of central cholinergic neurons in Alzheimer's dementia. Lancet 1976; 2: 1403.
3. Davies P, Verth AH. Regional distribution of muscarinic acetylcholine receptor in normal and muscarinic neurons in Alzheimer's dementia. Brain Res 1978; 138: 385-92.
4. Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-9.
5. Cummings JL, Benson DF. In Cummings JJ, Benson DF, eds. Dementia: a clinical approach. 2 ed. Boston: Butterworth-Heinemann; 1992. p. 45-93.
6. Palmer AM, Sims NR, Bowen D, Neary D, Palo J, Wikstrom J, et al. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia. J Neurol Neurosurg Psychiatr 1984; 47: 481-4.
7. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 19: 122-6.
8. Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A postmortem study of amino acid neutransmitters in Alzheimer's disease. Ann Neurol 1986; 20: 616-21.
9. Giacobini E, De Sarno P, Clark B, McIlhany M. The cholinergic receptor system of the human brain: the neurochemical and pharmacological aspects in aging and Alzheimer. Prog Brain Res 1989; 79: 343-53.
10. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development-a study of molecular forms. Neurochem Int 1992; 21: 381-96.
11. Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A postmortem study of the cholinergic and GABA systems in senile dementia. Brain 1982; 105: 313-30.
12. Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci 1981; 51: 279-87.
13. Bondareff W, Mountjoy CQ, Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 1982; 32: 164-8.
14. Perry EK, Tomlinson BE, Blessed G, Perry R, Cross AJ, Crow TT. Noradrenergic and cholinergic systems in senile dementia of Alzheimer's type. Lancet 1981: 149.
15. Bartus RT, Dean RL III, Beer D, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science1982; 217: 408-17.
16. Perry EK. The cholinergic system in old age and Alzheimer's disease. Age Ageing 1980; 9: 1-8.
17. Court JA, Perry EK. Dementia: the neurochemical basis of putative transmitter orientated therapy. Pharmacol Ther1991; 52: 423-43.
18. Mesulam M. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease. In Giacobini E, ed. Cholinesterase and cholinesterase inhibitors. London: Martin Donitz; 2000. p. 121-37.
19. Schoroder H, Zilles K, Maelicke A, Hajos F. Immunohisto-and cytochemical localization of octical nicotinic cholinoceptors in rat and man. Brain Res 1989; 502: 287-95.
20. Schroder H, Zilles K, Luiten PGM, Strosberg AD, Aghci A. Human cortical neurons contain both nicotinic and muscarinic acetylcholine receptors: an immunocytochemical double-labeling study. Synapse 1989; 4: 319-26.
21. Flynn DD, Ferrari DI, Leo G, Levey AI, Mash DC. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. Life Sci 1995; 56: 869-76.
22. Rodríquez-Puertas R, Pascual J, Vilaro T, Pazos A. Autoradiographic distribution of M1, M2, M3 and M4 muscarinic receptor subtypes in Alzheimer's disease. Synapse 1997; 26: 341-50
23. Nordberg A, Jelic V, Arnaiz E, Lanstrom, Almqvist O. Brain functional imaging in early and preclinical Alzheimer's disease. In Iqbal K, Sisodia S, Windblad B, eds. Alzheimer disease: advances in etiology, pathogenesis and therapeutics. Chichester, UK: John Wiley & Sons; 2001. p. 153-64.
24. Mori F, Lai CC, Fusi F, Giacobini E. Cholinesterase inhibitors increase secretion of APPS in rat brain cortex. Neuroreport 1995; 6: 633-6.
25. Emmerling MR, Schwarz RD, Spiegel K, et al. New perspectives on developing muscarinic agonists for treating Alzheimer's disease. ID Research Alert 1997; 2: 187-94.
26. Esler WP, Wolfe MS. A portrait of Alzheimer secretases: new familiar faces. Science 2001; 293: 1449-54.